Two Studies Presented at ASH 2024 Confirm Value of Hemex Health’s Gazelle Diagnostic Device in National Health Initiatives Focused on Hemoglobin Variants

Innovative Diagnostic​ Device Shows Promise in Fight⁣ Against Hemoglobinopathies

San Diego,Dec. 10, 2024 – Hemex Health announced promising results from studies evaluating the gazelle™ Diagnostic Device, ⁢a point-of-care tool designed ⁢to accurately diagnose hemoglobinopathies ⁢like sickle cell disease⁤ (SCD) adn ⁢beta thalassemia. The findings were presented at​ the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.The studies, conducted in Türkiye and India, highlight Gazelle’s potential to revolutionize screening efforts in countries with high prevalence of these debilitating​ genetic disorders. ⁣Both nations have implemented robust public health initiatives to mitigate the impact of hemoglobinopathies, and Gazelle offers a powerful new tool to support these efforts.

“National public health initiatives ​focused on screenings for ​sickle cell disease and⁣ beta thalassemia are essential to early detection,” said Patti White, CEO of hemex Health. “Our work with Gazelle demonstrates ⁣how innovative, point-of-care diagnostic tools can complement these efforts,‍ providing ‍a low-cost, accurate, and efficient alternative to conventional screening methods. Gazelle’s proven ⁢performance in diverse settings⁢ highlights its potential to expand access to critical diagnostics, ultimately ​saving lives and improving outcomes in communities that ‍need it most.”

Gazelle: A Game-Changer for Hemoglobinopathy Screening

The two⁢ poster presentations at ASH detailed the device’s performance in distinct settings:

Premarital Screening of Beta Thalassemia and Sickle Cell in Türkiye: This study evaluated‌ Gazelle’s ability to accurately​ identify SCD and⁤ beta thalassemia as a potential replacement for high performance liquid chromatography⁤ (HPLC), the current gold standard for screening. Researchers found ​Gazelle to be a consistent and reliable alternative ⁢to HPLC, offering a more accessible and cost-effective solution for⁣ premarital screening. The findings support ​Türkiye’s national beta⁢ thalassemia ​prevention program, which aims to increase screening⁣ rates in high-prevalence provinces.

Identification of Diverse Hemoglobinopathies in India: This study explored Gazelle’s ability to identify a wide range of hemoglobinopathies prevalent in⁤ India. The results demonstrated Gazelle’s versatility and⁤ accuracy in detecting diverse genetic variations, highlighting its potential to improve diagnostic ⁤capabilities​ in regions with high genetic diversity.

Hemex Health believes Gazelle’s success in these studies paves the way for ‍wider adoption of this innovative technology, ultimately leading to earlier diagnosis, ⁢improved treatment outcomes, and a brighter⁢ future for individuals affected by hemoglobinopathies ⁢worldwide.

Innovative Diagnostic Tool Shows Promise in⁢ Fight⁣ Against Sickle Cell Disease in India

new research ‍highlights the potential of Gazelle, a‌ portable diagnostic device, to revolutionize sickle cell disease (SCD) screening in India, a country grappling with a high prevalence of the debilitating ⁣genetic disorder.

The study, presented at the American ‍Society of ‌Hematology (ASH) Annual Meeting, evaluated Gazelle’s effectiveness in comparison to high-performance liquid chromatography (HPLC), ⁤the current gold standard for hemoglobin variant screening. Researchers focused‍ on West Bengal and Odisha, two Indian states with a notably high incidence ⁤of SCD and other hemoglobinopathies.

Gazelle accurately identified ⁢and quantified⁢ multiple abnormal hemoglobin variants in these‌ regions, demonstrating its ability to perform at the same level as HPLC. This ‌finding is ‌particularly notable given the urgent need for accessible and affordable screening tools in resource-limited​ settings.

“National public health ​initiatives focused on screenings for ⁣sickle cell disease and beta thalassemia are essential to early detection,” said Patti White, CEO of ⁤hemex health, the company behind‌ Gazelle. “Our work with Gazelle demonstrates how innovative, point-of-care diagnostic tools can complement these efforts, providing ​a low-cost, accurate, and efficient alternative to traditional screening methods. Gazelle’s proven performance in diverse settings highlights its potential to expand access ‍to critical diagnostics,⁤ ultimately ‌saving lives​ and improving outcomes in communities that need it most.”

The study’s findings come at a crucial time.​ India recently launched the National Sickle Cell Anemia‍ Elimination Mission (NSCAEM) in July 2023, aiming⁣ to eliminate SCD as a public​ health problem. ​ ‌

A Silent Threat: ‍The⁢ Impact of SCD and Beta Thalassemia

SCD and beta thalassemia, another inherited blood disorder, ‌pose a significant health burden ⁢in india and globally. These conditions not only cause debilitating symptoms but also increase⁢ the risk of severe complications, including pneumonia, malaria, and diarrhea.

Research‍ from the Institute for Health ‌Metrics and Evaluation (IHME) shows‍ that individuals ‍with either disorder are more likely to die from these common diseases.

Gazelle: ​A Beacon of Hope

Gazelle’s portability, affordability, and ease of use‍ make it a promising tool for expanding access to SCD screening, particularly in remote and underserved areas. The device utilizes artificial intelligence, innovative optics, and‍ miniaturization ⁢to deliver accurate⁢ results, empowering⁣ healthcare workers to diagnose and manage these conditions more effectively.

The success of Gazelle in india could pave the way for its wider adoption in other countries struggling with the burden of SCD and beta thalassemia. By ​providing a reliable and accessible diagnostic solution, Gazelle has the potential‍ to transform the landscape ​of⁤ sickle cell care and improve the lives of millions worldwide.

Revolutionizing Healthcare Access:‌ Gazelle Brings Affordable Diagnostics to Underserved Communities

Portland, OR – In a world were access to healthcare remains a significant challenge for millions, ⁤Hemex health is making strides with its innovative diagnostic platform, Gazelle.This portable, digital solution is ​transforming healthcare delivery in ‍resource-limited settings, empowering healthcare workers​ to provide accurate and timely diagnoses even in the most challenging environments.

Gazelle is designed for entry-level ‍healthcare workers and operates effectively in​ locations with limited access to electricity or resources. The platform digitally captures patient details and test results, allowing for ⁣secure storage, printing, or later transmission. This eliminates⁤ the need for bulky equipment and complex procedures, making⁣ diagnostics accessible to even the most remote communities.

One of Gazelle’s key applications is in identifying Hb variants, which plays ⁣a⁢ crucial role in diagnosing sickle ‍cell disease and beta thalassemia. The platform is already ⁢making a ⁣difference in over 40‌ countries,providing a lifeline to individuals​ who previously lacked access to these vital tests.

“Gazelle represents a paradigm shift in ‌healthcare accessibility,” says [Spokesperson Name and Title at Hemex health]. “Our goal is to democratize diagnostics, ensuring that everyone,⁢ irrespective of their location or economic status, ​has ⁢access to accurate ‍and ⁤timely healthcare.”

The versatility of Gazelle allows Hemex Health to continually expand its diagnostic menu, addressing a wider range of health concerns and reaching even more users. This commitment to ​innovation and inclusivity positions ‍Gazelle as a powerful tool ⁤in​ the fight against global health disparities.

Learn⁢ more about Gazelle and Hemex Health’s mission to revolutionize‍ healthcare access at [link to Hemex Health website].

New⁣ Diagnostic Device Could Be Game-Changer in Fight ​Against Hemoglobinopathies

New Directiory3 Exclusive Interview

San Diego, CA (December 10, ⁢2024) – A new point-of-care diagnostic ‌tool​ called ⁣Gazelle™ is making waves in the​ fight against hemoglobinopathies like sickle cell disease (SCD) ⁣and beta thalassemia. ⁢Presented at⁤ the 66th⁤ American Society of Hematology (ASH) Annual Meeting, the device showed impressive results in studies conducted in Türkiye and India. We spoke with Patti white, ⁤CEO of Hemex Health, the company behind ⁣Gazelle, to understand its potential ⁤impact on global healthcare.

NewsDirect3: What makes Gazelle ⁢stand out from⁤ existing screening methods?

Patti⁣ White: Traditionally, Hemoglobinopathies have been screened ⁣using high-performance liquid chromatography (HPLC), which is expensive ⁢and requires sophisticated ⁤laboratory infrastructure. Gazelle changes the game. It’s a portable, affordable​ device that‌ provides accurate results right at the point of care, ​making it ideal for resource-limited settings.

ND3: The studies⁤ presented at ASH​ showed promising results in both ‍Türkiye and ⁤India. can you elaborate on those findings?

PW: Absolutely. In Türkiye, gazelle successfully identified SCD and beta thalassemia cases, proving its effectiveness as a replacement for ​HPLC‌ in premarital screening programs.This is notable because Türkiye has ⁣implemented‍ a national beta thalassemia prevention program, ⁤and Gazelle​ can play a crucial role ⁤in expanding screening efforts.

In⁤ India, Gazelle demonstrated remarkable⁤ accuracy in detecting diverse ⁢hemoglobinopathies prevalent in the country, including SCD. This highlights its versatility and potential to ‍revolutionize screening ‌in areas with high genetic diversity.

ND3: How ​can Gazelle‍ impact patients living with ⁣hemoglobinopathies?

PW: Early‌ detection is key for managing these conditions.

Gazelle allows⁣ for⁣ timely diagnosis, enabling individuals to​ access appropriate treatment and care sooner.this can significantly improve ⁣their quality of life and overall health outcomes.

ND3:⁢ What are the next steps for Hemex ‍Health​ and Gazelle?

PW: We are incredibly encouraged by ⁣the results of these studies. Our⁢ goal is to ‍make gazelle widely accessible⁤ in countries⁢ with a high burden of hemoglobinopathies.‍ We are actively pursuing collaborations ​with ‌healthcare​ providers, NGOs, and governments to integrate Gazelle into​ existing national health programs.

ND3: ⁢What does‌ this innovation ​mean for the ​fight against sickle cell disease globally?

PW: Gazelle represents​ a powerful tool in our arsenal.It gives us the potential to bring accurate, affordable ⁣diagnosis to​ marginalized communities where access ‍to healthcare is⁤ often⁢ limited. ⁤We‍ beleive Gazelle can definitely help turn the tide against⁢ hemoglobinopathies, leading to a future where everyone has ‍the opportunity for‌ early⁤ detection and effective management.

Hemex Health’s‌ Gazelle device represents a significant advancement in the ⁣fight against⁣ hemoglobinopathies. Its affordability,⁤ portability, ⁢and accuracy hold⁤ the promise of transforming healthcare ‌access and ultimately saving lives.